ライフサイエンスコーパス: fentanyl

1 onism on demand for the highly abused opioid fentanyl.

2 ed hyperalgesia (OIH) and priming induced by fentanyl.

3 n of proteins that bind the potent analgesic fentanyl.

4 ions than ketamine combined with propofol or fentanyl.

5 d analgesia with potent opioid drugs such as fentanyl.

6 nction of opioid drugs, such as morphine and fentanyl.

7 Strategy for Transmucosal Immediate-Release Fentanyl.

8 ed with differences in sensitivity to MA and fentanyl.

9 nternalization induced by either morphine or fentanyl.

10 sult in more rapid recovery as compared with fentanyl.

11 locomotor stimulant response to both MA and fentanyl.

12 ensitivity to the mu-opioid receptor agonist fentanyl.

13 00 persons, 85% of which involved the use of fentanyl.

14 hypokalemia additively reduced I(hERG) with fentanyl.

15 able 18% diluted Ensure(R) (liquid food) and fentanyl (0-10 mug/kg/infusion) infusions during daily s

16 monkeys self-administered i.v. infusions of fentanyl (0.00032 mg/kg/infusion) or cocaine (0.032 mg/k

17 Furthermore, fentanyl (0.5 muM) prolonged AP duration and blocked I(K

18 When fentanyl (0.5 nm) was applied to dorsal root ganglion (D

19 ane (300 mum) significantly inhibited, while fentanyl (1 mum) significantly enhanced, EPSC amplitude

20 food pellets for 6 d (6 h/d) and intravenous fentanyl (2.5 mug/kg/infusion) for 12 d (6 h/d).

21 a sample of fentanyl-laced heroin (1.3 wt % fentanyl, 2.6 wt % heroin, and 96.1 wt % lactose).

22 am (NaCl, interspinous L(3)-L(4)) or active (fentanyl 25 mug, intrathecal L(3)-L(4)) spinal anesthesi

23 larly, the reinforcing effectiveness of both fentanyl (3.2 and 10 ug/kg per injection, IV) and dilute

24 ically increased by morphine (2-fold) and by fentanyl (3.8-fold).

25 neous administration of an analgesic dose of fentanyl (30 mug/kg, s.c.) was performed in vivo in male

26 The combinations of ketamine and fentanyl (4.1%; OR, 4.0; 95% CI, 1.8-8.1) and ketamine a

27 orted as the most frequently used sedatives; fentanyl (44%) and morphine (20%) the most frequent opio

28 mia decreased the systemic clearance of both fentanyl (61.5 +/- 11.5 to 48.9 +/- 8.95 mL/min/kg; p <

29 antly prolonged after spinal anesthesia with fentanyl (639 +/- 87 s vs. 423 +/- 38 s [mean +/- SEM];

30 ew years we and others have used intrathecal fentanyl, a mu-opiate receptor agonist, in humans to red

31 ecular dynamics simulations to determine how fentanyl, a potent beta-arrestin biased agonist, binds t

32 tion of central motor output via intrathecal fentanyl: (a) reduced the mean arterial blood pressure (

33 isplayed enhanced survival when subjected to fentanyl above LD(50) doses.

34 Fentanyl abuse poses a serious health concern, with abus

35 man morbidity and mortality linked to acetyl fentanyl abuse.

36 A dramatic improvement in the separation of fentanyl, alfentanil, 4-aminophenyl-1-phenethylpiperidin

37 nent mixtures: drugs of abuse, peptides, and fentanyl analogs.

38 ation and detection of fentanyl and nine (9) fentanyl analogues from mixtures.

39 The increasing prevalence of fentanyl and fentanyl analogues in mixtures with heroin and other adu

40 ncy of synthetic opioids (e.g., fentanyl and fentanyl analogues), leading to an increase in adulterat

41 nyl, yet broad cross-reactivity with related fentanyl analogues.

42 es with cross-reactivity for a wide panel of fentanyl analogues.

43 anyl contained high concentrations of acetyl fentanyl and acetyl norfentanyl.

44 ad mAb (6A4) could blunt the effects of both fentanyl and carfentanil in a dose-responsive manner.

45 the high-efficacy mu opioid receptor agonist fentanyl and characterized MCAM pharmacokinetics.

46 nduced in vivo by systemic administration of fentanyl and confirmed by prolongation of prostaglandin

47 lysis, and a concurrent (choice) schedule of fentanyl and diluted Ensure((R)) reinforcement in Spragu

48 The increasing prevalence of fentanyl and fentanyl analogues in mixtures with heroin

49 extreme potency of synthetic opioids (e.g., fentanyl and fentanyl analogues), leading to an increase

50 The increasing prevalence of fentanyl and its analogues as contaminating materials in

51 nd toxicity in mice and rats challenged with fentanyl and its analogues.

52 Fentanyl and its derivatives have a low lethal dose and

53 able methods for analyzing compounds such as fentanyl and its derivatives is increasingly important.

54 y from accidental and deliberate exposure to fentanyl and its derivatives.

55 onfidence, which serves as a basis to detect fentanyl and its derivatives.

56 wide due to the widespread access to illicit fentanyl and its potent analogues.

57 or the simultaneous quantification of acetyl fentanyl and its predicted metabolite, acetyl norfentany

58 The mean daily dosing of fentanyl and lorazepam decreased after the intervention.

59 actions of other opioid analgesics, such as fentanyl and methadone.

60 Time to first coma was associated with fentanyl and midazolam doses (p=0.03 and p=0.01, respect

61 Coma is associated with fentanyl and midazolam exposure; delirium is unrelated t

62 Bolus dosing of fentanyl and midazolam fails to reduce the intracranial

63 pothermia reduces the systemic clearances of fentanyl and midazolam in rats after cardiac arrest thro

64 Fentanyl and midazolam were independently administered b

65 pothermia on the in vivo pharmacokinetics of fentanyl and midazolam, two clinically relevant cytochro

66 However, selective MOR agonists including fentanyl and morphine derivatives are limited clinically

67 nly used clinical opioid analgesics, such as fentanyl and morphine, can produce hyperalgesia and chro

68 repolarization after a 50 mV depolarization, fentanyl and naloxone blocked hERG current (I(hERG)) wit

69 are wave voltammetric (SWV) detection of the fentanyl and nerve agent targets, respectively.

70 employed for the separation and detection of fentanyl and nine (9) fentanyl analogues from mixtures.

71 prevalence and duration of delirium, use of fentanyl and open-label midazolam, and nursing assessmen

72 Specifically, fentanyl and related analogues such as carfentanil pose

73 MS-mass spectrometry (MS) in the analysis of fentanyl and related compounds is presented herein with

74 e higher with oxycodone-naloxone followed by fentanyl and tapentadol.

75 n in-silico derived hypothesis we found that fentanyl and the synthetic opioid peptide DAMGO require

76 pertension increased after administration of fentanyl and/or midazolam (overall aggregate mean Deltaa

77 te epochs before and after administration of fentanyl and/or midazolam for the treatment of episodic

78 including chemical warfare agent simulants, fentanyls and other opioids, amphetamines, cathinones, a

79 g of opioids for pain and the illicit use of fentanyl (and derivatives) have contributed to the curre

80 receptor desensitization, whereas etorphine, fentanyl, and [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin (DAM

81 ntravenous self-administration of oxycodone, fentanyl, and buprenorphine in rats allowed long access

82 Quantitative determination of clenbuterol, fentanyl, and buprenorphine was successfully achieved in

83 Phosphorylation blockage made etorphine, fentanyl, and DAMGO function as morphine in the primary

84 ng dominant-negative GRK2 enabled etorphine, fentanyl, and DAMGO to activate PKCepsilon.

85 Thr370 and Ser375 to Ala) enabled etorphine, fentanyl, and DAMGO to use the PKCepsilon pathway.

86 cit drugs (cocaine, methamphetamine, heroin, fentanyl, and its analogues), adulterants, and diluents

87 Using FSA, oxycodone, hydrocodone, fentanyl, and their urinary metabolites were quantified

88 ed for tetraalkylammonium salts, explosives, fentanyls, and amphetamines.

89 Prophylactic vaccination reduced fentanyl- and sufentanil-induced antinociception, respir

90 lockers, drugs of abuse (methamphetamine and fentanyl), anesthetics, neurotoxins, the pesticide paraq

91 a rapid and short-acting synthetic analog of fentanyl, appears to offer clinically significant advant

92 d analgesic responses to morphine but not to fentanyl are moderated by OPRM1 A118G variation, but the

93 that betaarrestin-biased compounds, such as fentanyl, are more likely to induce respiratory suppress

94 Opioids, such as morphine and fentanyl, are widely used for the treatment of severe pa

95 Most intensivists chose fentanyl as their first-line opioid (66%) and midazolam

96 g rats to examine the effects of intravenous fentanyl at doses within the range of possible human int

97 tional framework for further optimization of fentanyl-based analgesics with improved safety profiles.

98 h a novel M153 "microswitch" by synthesizing fentanyl-based derivatives that exhibit complete, clinic

99 of vaccine formulations consisting of novel fentanyl-based haptens conjugated to carrier proteins.

100 Furthermore, fentanyl blockade prevented the significant increase in

101 tions, but this reduction was prevented with fentanyl blockade.

102 embling native I(Kr) Our results showed that fentanyl blocked hERG1a/1b channels with a 3-fold greate

103 ventricular action potential (AP) was used, fentanyl blocked I(hERG) with an IC(50) of 0.3 muM.

104 We have demonstrated that fentanyl blocks hERG current (I(hERG)) at concentrations

105 The resulting fentanyl-bound pose provides rational insight into a wea

106 ified miRNAs, miR-190, was down-regulated by fentanyl but not by morphine.

107 90 (miR-190) in an agonist-dependent manner; fentanyl, but not morphine, decreases the miR-190 level

108 se the designs to generate plant sensors for fentanyl by coupling ligand binding to design stability.

109 1b in the human heart, hERG channel block by fentanyl can be exacerbated by certain conditions, such

110 Since fentanyl can cause respiratory depression and electrolyt

111 lly used mu-opioid receptor agonists such as fentanyl can produce hyperalgesia and hyperalgesic primi

112 During peak exercise with fentanyl, cardiac output was 12% greater in HFrEF second

113 astly, the 6A4 mAb could effectively reverse fentanyl/carfentanil-induced antinociception comparable

114 This work provides the most detailed fentanyl CAS investigation to date by using orthogonal m

115 3-13.1) and the combinations of ketamine and fentanyl citrate (3.2%; OR, 6.5; 95% CI, 2.5-15.2) and k

116 apy for reducing the psychoactive effects of fentanyl class drugs.

117 ped monoclonal antibodies (mAbs) against the fentanyl class of drugs.

118 VO2 peak was 15% greater with fentanyl compared with placebo for HFrEF (P < 0.01), whi

119 With fentanyl, compared with placebo, patients with HFrEF ach

120 ormation-rich electrochemical fingerprint of fentanyl, composed of an initial oxidation event at +0.5

121 adulterants and excipients at 30:1 (compound/fentanyl) concentration ratios.

122 hourly drug administration data and measured fentanyl concentrations in plasma collected once daily f

123 , and congestive heart failure most affected fentanyl concentrations.

124 dyspnea was significantly flatter during the fentanyl condition than with placebo.

125 ate were reduced at isotime points under the fentanyl condition, whereas ventilatory efficiency and d

126 bridomas derived from mice vaccinated with a fentanyl conjugate vaccine.

127 rom rats treated with a toxic dose of acetyl fentanyl contained high concentrations of acetyl fentany

128 After 3 d of treatment, morphine and fentanyl decreased the activity of the Ca(2+)/calmodulin

129 Thus, fentanyl decreased the transcription of talin2 and subse

130 vel of its host gene, talin2, suggested that fentanyl decreases the miR-190 level by inhibiting the t

131 f abuse, including opioids, benzodiazepines, fentanyl derivatives, methamphetamines, cocaine, substit

132 f fatalities have been linked to overdose of fentanyl derivatives.

133 considerable promise for rapid decentralized fentanyl detection at the "point of need".

134 rr][NTf(2)], toward such rapid "on-the-spot" fentanyl detection.

135 he metabolic pathways responsible for acetyl fentanyl detoxification and excretion.

136 ary cultures from beta-arrestin2(-/-) mouse, fentanyl did not decrease the expression of miR-190.

137 cal in the TCR, and ketamine, isoflurane and fentanyl differentially alter the synaptic pathways via

138 epam dose (p = 0.012), and higher cumulative fentanyl dose (p = 0.035) were administered in the delir

139 ntability experiments by increasing the unit fentanyl dose available during the self-administration s

140 e selective mu opioid receptor (MOR) agonist fentanyl dose-dependently facilitates gregarious song an

141 The fentanyl dose-effect function under the FR5 schedule was

142 ce gained significant protection from lethal fentanyl doses.

143 udies are needed to determine if data-driven fentanyl dosing algorithms can improve outcomes for ICU

144 ng device capable of continuously monitoring fentanyl down to the nanomolar level through a nanomater

145 offer clinically significant advantages over fentanyl during outpatient anesthesia.It is reasonable t

146 Up-regulation of miR-339-3p by fentanyl (EC(50)=0.75 nM) resulted from an increase in p

147 pioid exposures (odds ratio, 3.3 per 100 mug fentanyl equivalent/kg; 95% CI, 0.90-16), and paralytic

148 l [CI], 1.03-3.95; P = 0.04), an increase in fentanyl equivalents administered to patients at night (

149 orphine (11.6%; 95% CI, 11.2% to 11.9%), and fentanyl family (10.2%; 95% CI, 9.8% to 10.5%).

150 escribed for lung and colorectal cancers and fentanyl family for head and neck cancers (PR, 1.39; 95%

151 the tampering outbreaks, six (75%) involved fentanyl, five (63%) occurred in the United States, and

152 odular' anesthesia that combined injectable (fentanyl-fluanisone/midazolam) and volatile (isoflurane)

153 ns and the mouse hippocampi with morphine or fentanyl for 3 days, seven miRNAs regulated by one or tw

154 the protein kinase C (PKC)-pathway, whereas fentanyl functions in a beta-arrestin2-dependent manner.

155 analyzed, 129 in alfentanil group and 131 in fentanyl group.

156 As fentanyl has a propensity to cause sudden death, we inve

157 Fentanyl has emerged as a recreational drug, often in co

158 The synthetic nature of fentanyl has enabled the creation of dangerous "designer

159 with increased use of drugs like heroin and fentanyl, has led to an epidemic in addiction and overdo

160 e's data to compare UDT results for cocaine, fentanyl, heroin, and methamphetamine before vs after US

161 ntrol conditions and with lumbar intrathecal fentanyl impairing feedback from mu-opioid receptor-sens

162 onditions (CTRL) and with lumbar intrathecal fentanyl impairing lower limb muscle afferent feedback (

163 acebo conditions and with lumbar intrathecal fentanyl impairing spinal mu-opioid receptor-sensitive g

164 ation by FTIR-ATR, enabled identification of fentanyl in a sample of fentanyl-laced heroin (1.3 wt %

165 or direct quantification of the illicit drug fentanyl in red blood cell extracts.

166 etic, but the basic physiological effects of fentanyl in the brain when taken as a drug of abuse are

167 actors that should be considered when dosing fentanyl in the ICU.

168 of JNK and cJun, and that morphine, but not fentanyl, increased the nuclear localization of the phos

169 fferentially by mu-opioid receptor agonists; fentanyl increases NeuroD level by reducing the amount o

170 Fentanyl induced a rapid, dose-dependent decrease in NAc

171 Fentanyl induced similar oxygen decreases in the basolat

172 Fentanyl-induced beta-arrestin2-mediated ERK phosphoryla

173 certain pathologic circumstances exacerbate fentanyl-induced block of I(hERG) Our results show that

174 gs in the subcutaneous space to confirm that fentanyl-induced brain hypoxia results from decreases in

175 When fentanyl-induced but not morphine-induced ERK phosphoryl

176 xia and a subsequent rise in CO2 that drives fentanyl-induced increases in NAc glucose.

177 Together, these data suggest that fentanyl-induced respiratory depression triggers brain h

178 or alkalosis, which may increase the risk of fentanyl-induced ventricular arrhythmias and sudden deat

179 ngs in the NAc, muscle, and skin showed that fentanyl induces biphasic changes in brain temperature,

180 rsed in vivo Thus, in vivo administration of fentanyl induces neuroplasticity in weakly IB4+ and IB4-

181 Thus, in vivo administration of fentanyl induces nociceptor neuroplasticity, which persi

182 through a discrete choice procedure between fentanyl infusions and palatable food (20 trials/d).

183 ocedure, males chose 3.2 ug/kg per injection fentanyl injections over 18%, but not 56%, diluted Ensur

184 Therapeutic vaccination also reduced fentanyl intravenous self-administration in rats.

185 Fentanyl is a potent synthetic opioid used extensively i

186 Fentanyl is an addictive prescription opioid that is ove

187 Fentanyl is an anesthetic with a high bioavailability an

188 n functional groups that are constituents of fentanyl is determined by investigating the structure-pr

189 vivo rodent studies demonstrated that acetyl fentanyl is metabolized by cytochrome P450s to acetyl no

190 However, fentanyl is New Taiwan Dollar (NT$) 103 (approximate US$

191 However, fentanyl is NT$103 (US$ 4) cheaper than alfentanil in ea

192 Fentanyl is well characterized as an anesthetic, but the

193 ture, alfentanil and ortho-isopropyl furanyl fentanyl, is demonstrated without lengthy chromatography

194 ed identification of fentanyl in a sample of fentanyl-laced heroin (1.3 wt % fentanyl, 2.6 wt % heroi

195 From placebo to fentanyl, leg VO2 , QL and O(2) delivery were greater fo

196 carfentanil, furanyl fentanyl, methoxyacetyl fentanyl, MAB-CHMINACA, methcathinone, 4-methyl pentedro

197 er baseline and saline treatment conditions, fentanyl maintained a dose-dependent increase in fentany

198 midazolam (102 mg/d vs 82 mg/d; P = .04) and fentanyl (median [IQR], 550 [50-1850] vs 260 [0-1400]; P

199 these results provide molecular insight into fentanyl mediated beta-arrestin biased signaling and a r

200 As well, high pH potentiated the fentanyl-mediated block of hERG channels, with an IC(50)

201 However, fentanyl-mediated block of I(hERG) was voltage dependent

202 vation mechanism where the n-aniline ring of fentanyl mediates muOR beta-arrestin through a novel M15

203 nown immunosuppressive properties (morphine, fentanyl, methadone) to the infection risk among patient

204 rast, a second class of mu-opioids including fentanyl, methadone, and oxycodone produced acute analge

205 Nine NPSs (carfentanil, furanyl fentanyl, methoxyacetyl fentanyl, MAB-CHMINACA, methcath

206 Common drugs implicated included propofol, fentanyl, metoprolol, lorazepam, hydralazine, and furose

207 of alfentanil, midazolam and propofol versus fentanyl, midazolam and propofol in 272 outpatients unde

208 The additional doses of fentanyl, midazolam, and propofol required for CAE were

209 sics: oxycodone, hydrocodone, hydromorphone, fentanyl, morphine, and tramadol.

210 age, sex, PMA, dose of analgesics/sedatives (fentanyl, morphine, midazolam), mechanical ventilation,

211 Intravenous infusion narcotics (fentanyl, morphine, or hydromorphone) were used more fre

212 sociated with the synthesis of the analgesic fentanyl, N-(1-phenylethylpiperidin-4-yl)-N-phenylpropan

213 lume urine assay for oxycodone, hydrocodone, fentanyl, noroxycodone, norhydrocodone, and norfentanyl

214 gnaling pathway that mediates the effects of fentanyl on miR-190 expression.

215 V afferent inhibition via lumbar intrathecal fentanyl on peak exercise capacity ( VO2 peak) and the c

216 anisms of action of ketamine, isoflurane and fentanyl on the synaptic TCR responses in both neurones

217 activated by opioid agonist treatment (10 nM fentanyl or 10 muM morphine), a specific effect blocked

218 o determine VO2 peak with lumbar intrathecal fentanyl or placebo.

219 o determine VO2 peak with lumbar intrathecal fentanyl or placebo.

220 s outbreaks, injection of opioids (including fentanyl) or methamphetamine predominated; many PWID con

221 at animals that self-administered oxycodone, fentanyl, or heroin, but not buprenorphine had similar p

222 etabolite, and naloxone, an antidote used in fentanyl overdose, were also examined.

223 oncentration (P < .0001), concomitant use of fentanyl (P = .008) and ketoconazole (P = .03), and age

224 nificantly after administration of high-dose fentanyl (p = 0.02), low-dose midazolam (p = 0.006), and

225 e to prescribe methadone, recognize risks of fentanyl patches, titrate cautiously, and reduce doses b

226 characteristics of these anodic and cathodic fentanyl peaks, generated using two CSWV cycles, thus le

227 ty of illness was marginally associated with fentanyl pharmacokinetics but did not improve the model

228 In this study, fentanyl pharmacokinetics during critical illness were s

229 s model implemented by NONMEM, we found that fentanyl pharmacokinetics were best described by a two-c

230 ow-dose midazolam (p = 0.006), and high-dose fentanyl plus low-dose midazolam (0.007).

231 is can increase the block of hERG current by fentanyl, potentially increasing the risk of cardiac arr

232 e on the toxicology and metabolism of acetyl fentanyl precludes its detection in human samples.

233 timulated [(35)S]GTPgammaS binding following fentanyl pretreatment was not blocked by JNK inhibition.

234 l root ganglion (DRG) neurons, cultured from fentanyl-primed rats, and rats with OIHP treated with ag

235 d and tested against CAS profiles from crude fentanyl products deposited and later extracted from two

236 Additionally, 2 d after systemic fentanyl, rats had also developed hyperalgesic priming (

237 vaccine administration significantly blunted fentanyl reinforcement and increased food reinforcement

238 ATEMENT There are few preclinical studies of fentanyl relapse, and these studies have used experiment

239 range of postmortem blood concentrations in fentanyl-related deaths.

240 s applied in a systematic manner to identify fentanyl-related functional groups in such compounds bas

241 applied to a few adjudicated case samples of fentanyl-related mixtures exhibiting dyes and visible pa

242 Although mechanisms of fentanyl-related sudden death need further investigation

243 mined whether clinically employed synthetic (fentanyl, remifentanil) and the semisynthetic opioid (ox

244 (DRG) neurons cultured from rats primed with fentanyl, robust nociceptor population-specific changes

245 We assessed relapse to fentanyl seeking after 13-14 voluntary abstinence days,

246 muscimol plus baclofen decreased relapse to fentanyl seeking after voluntary abstinence.

247 Relapse to fentanyl seeking was associated with increased Fos expre

248 the Pir and OFC are critical for relapse to fentanyl seeking.

249 lofen (50 + 50 ng/side) decreased relapse to fentanyl seeking.

250 ) and its afferent projections in relapse to fentanyl seeking.

251 redicted the amount of cued reinstatement of fentanyl seeking; this reinstatement behavior was attenu

252 Repeated MCAM administration decreased fentanyl self-administration for more than 2 months with

253 ute injection, MCAM and naltrexone decreased fentanyl self-administration on the day of treatment, wi

254 yl-tetanus toxoid conjugate vaccine to alter fentanyl self-administration using a fentanyl-vs.

255 Sex differences in intravenous (IV) fentanyl self-administration were examined under a fixed

256 ailability unmasked genotypic differences in fentanyl sensitivity.

257 Etonitazene and fentanyl stimulated the in vivo phosphorylation of multi

258 Purpose Fentanyl sublingual tablets (FST) are a potentially usef

259 on methods of both known and emerging opioid fentanyl substances is crucial.

260 al model capable of predicting the method of fentanyl synthesis was validated and tested against CAS

261 synthesis methods, all previously published fentanyl synthetic routes or hybrid versions thereof, we

262 sent study determined the effectiveness of a fentanyl-tetanus toxoid conjugate vaccine to alter fenta

263 Transmucosal immediate-release fentanyls (TIRFs), indicated solely for breakthrough can

264 h) either with or without lumbar intrathecal fentanyl to attenuate group III/IV afferent feedback fro

265 s reduced by morphine, but maintained during fentanyl treatment.

266 evelopment was 67 +/- 10% greater during the fentanyl trial (P < 0.01).

267 ed 8 and 10% lower, respectively, during the fentanyl trial and these differences progressively dimin

268 cebo, significant hypoventilation during the fentanyl trial was indicated by the 9% lower V(E)/V(CO(2

269 vaccines as a viable strategy to counteract fentanyl use disorders and toxicity.

270 Illicit fentanyl use is associated with sudden death.

271 The concentrations of fentanyl used in this study were higher than seen with c

272 Lastly, fentanyl vaccine administration prevented the expression

273 First, fentanyl vaccine administration significantly blunted fe

274 Our newly developed fentanyl vaccine and analytical methods may assist in th

275 sion 10-fold empirically determined that the fentanyl vaccine produced an approximate 22-fold potency

276 tudy was to clarify this discrepancy using a fentanyl vs. diluted Ensure((R)) choice procedure to ass

277 However, under a fentanyl vs. foodchoice procedure, males chose 3.2 ug/kg

278 CMD was 9 +/- 3% higher at end-exercise with fentanyl vs. placebo (P < 0.05).

279 reater (-44 +/- 2% vs. -34 +/- 2%) following fentanyl vs. placebo.

280 h) treatment effects were also determined on fentanyl-vs.

281 uced an approximate 22-fold potency shift in fentanyl-vs.

282 anyl maintained a dose-dependent increase in fentanyl-vs.

283 ession of withdrawal-associated increases in fentanyl-vs.

284 o alter fentanyl self-administration using a fentanyl-vs.

285 Clonidine treatment significantly increased fentanyl-vs.

286 Two days later, when fentanyl was administered intradermally (1 mug, i.d.), i

287 This sensitizing effect of fentanyl was reversed in weakly IB4(+) DRG neurons cultu

288 Fentanyl was successfully separated and detected down to

289 Lumbar intrathecal fentanyl was used to attenuate the central projection of

290 To rule out a direct central effect of fentanyl, we documented unchanged resting cardioventilat

291 ditionally, greater amounts of lorazepam and fentanyl were administered to patients with delirium.

292 Plasma levels of fentanyl were higher in patients with clinical coma (3.7

293 ut the analgesic actions of heroin, M6G, and fentanyl were markedly diminished in the radiant heat ta

294 In contrast, the behavioral effects of fentanyl were neither genotype-dependent nor affected by

295 which did not cause MOR internalization, or fentanyl, which did.

296 m current in the human heart, are blocked by fentanyl with a 3-fold greater potency than the previous

297 accelerated narco-trafficking of heroin and fentanyl with consequent increases in opioid overdose mo

298 ocked tolerance by administering morphine or fentanyl with the PDGFR-beta inhibitor imatinib.

299 ) decreased motivation (increased alpha) for fentanyl without affecting Q(o).

300 ced mAbs with 10(-11) M binding affinity for fentanyl, yet broad cross-reactivity with related fentan